evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

43 questions · 43 findings · 7 reviews · Airways

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 1 · 2.3%Very low 2 · 4.7%Low 10 · 23.3%Moderate 26 · 60.5%High 4 · 9.3%

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Exacerbations (number of people experiencing ≥ 1 exacerbations) · stable COPD

Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in exacerbations (number of people experiencing ≥ 1 exacerbations) compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Number of participants experiencing any serious adverse events · stable COPD

Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in serious adverse events (number of people experiencing ≥ 1 SAEs) compared with LABA plus inhaled corticosteroid (ICS) (high certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Change in SGRQ total score · stable COPD

Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in quality of life as measured by SGRQ total score change from baseline… compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Change in baseline trough FEV1 · stable COPD

Long‐acting muscarinic antagonist (LAMA) plus long‐acting… probably leads to higher trough FEV1 change from baseline compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

All‐cause death · stable COPD

Long‐acting muscarinic antagonist (LAMA) plus long‐acting… probably leads to higher all‐cause death compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

SGRQ total score change from baseline (≥ 4 points, MCID) · stable COPD

Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in SGRQ total score change from baseline (≥ 4 points, MCID) compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).

1 finding from 1 review

Tiotropium vs long‐acting beta‐agonists

Hospitalisations, number of participants with 1 or more exacerbations · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history

Tiotropium probably leads to lower patients with 1 or more exacerbations compared with long‐acting beta‐agonists (moderate certainty).

1 finding from 1 review

Tiotropium vs long‐acting beta‐agonists

Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history

It is very uncertain whether tiotropium changes mortality (all‐cause) compared with long‐acting beta‐agonists (very low certainty).

1 finding from 1 review

IV + inhaled beta agonist vs inhaled beta‐agonist

Clinical Failure (children with a severe to moderate overall clinical assessment score at two hours) · patients with acute asthma

IV + inhaled beta agonist probably leads to lower clinical Failure (children with a severe to moderate overall… compared with inhaled beta‐agonist (moderate certainty).

1 finding from 1 review